Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05133765
Other study ID # SMART B
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 14, 2021
Est. completion date October 7, 2022

Study information

Verified date November 2022
Source Steno Diabetes Center Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Despite the established health benefits conveyed by physical activity for people with type 1 diabetes (T1D), participation rates remain low, with fear of hypoglycaemia, lack of freedom to engage in unplanned activities, and uncertainty in making appropriate adjustments to insulin and nutritional therapy reported as the leading barriers to regular exercise engagement. Indeed, the synergistic glucose lowering effects of peripheral hyperinsulinaemia and exercising muscle tissue accentuate the risk of exercise-related hypoglycaemia for individuals with T1D, particularly if performed post-prandially. Hence, the introduction of commercially available artificial pancreas systems, also known as ''advanced hybrid-closed-loop'' (AHCL) systems, that regulate insulin rates with minimal user interaction constitute compelling therapeutic aids with clinically relevant potential. Nevertheless, we know little about their safe and efficacious integration around dynamic physical exercise. Nor do we know how alterations in carbohydrate fueling strategies around exercise effect subsequent glucose trends. This study aims to 1) compare the efficacy of an AHCL system versus usual care insulin pump therapy, with carbohydrates taken before or during exercise, in optimising TIR around dynamic physical exercise and 2) explore the influence of carbohydrate intake before versus during exercise on the metabolomic, hormonal and physiological responses to exercise.


Description:

Following successful completion of a screening visit, participants will attend the laboratory to complete 3 experimental visits during which they will undertake a 45-minute bout of moderate intensity continuous exercise on a bicycle ergometer at ~60% of the individualised VȮ2max. Prior to commencing exercise, participants will consume a standardised low-glycaemic index, carbohydrate-based meal (equating to 0.75g.CHO.kg.bm-1) with, or without, a 25% reduction in their meal-time insulin dose as well as with carbohydrates before or during exercise (according to the randomisation). Venous blood glucose sampling will be taken in 15-minute intervals leading into and after exercise with 5-minute intervals performed during exercise. Samples will be used to retrospectively cross-compare the metabolic, hormonal, and physiological responses between visits. Visits 1 & 2 will be separated by ≥14 days to ensure adequate familiarisation with the AHCL system whilst visits 2 & 3 will be separated by ≥3days. Each participant will undertake 1 screening and 3 experimental visits equating to a total of 80 study visits.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date October 7, 2022
Est. primary completion date October 7, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - • Type 1 diabetes =2 years. - HbA1c; - 58-63 mmol/mol (maximum 30% of participants) OR - = 64 mmol/mol (minimum 70% of participants) - Insulin pump treatment =12 months - CGM or isCGM use =6 months - Novorapid use =4 weeks - Carbohydrate counting and use of the insulin pump bolus calculator for most snacks and meals. - Carbohydrate intake >80 grams per day (assessed by review of intake recorded in the insulin pump during the 2 weeks prior to the screening visit) Exclusion Criteria: - • Breast-feeding, pregnancy or planning to become pregnant. - Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start. - Use of hybrid closed-loop systems - Daily use of paracetamol (acetaminophen) - Alcohol or drug abuse. - Severe cardiac disease or retinopathy contraindicating HbA1c <53 mmol/mol. - Other concomitant medical or psychological condition that according to the investigator's assessment makes the person unsuitable for study participation. - Lack of compliance with key study procedures at the discretion of the investigator. - Unacceptable adverse events at the discretion of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Insulin pump
Alterations in insulin pump therapy or carbohydrate consumption

Locations

Country Name City State
Denmark Steno Diabetes Center Copenhagen Gentofte

Sponsors (2)

Lead Sponsor Collaborator
Steno Diabetes Center Copenhagen Swansea University

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Comparison of the maximum BG concentration Comparison of the maximum blood glucose concentration before, during and for 1 hour after physical exercise -90 minutes to +105 minutes
Other Comparison of the minimum BG concentration Comparison of the minimum blood glucose concentration before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other Comparison of standard deviation in BG concentrations Comparison of standard deviation in blood glucose concentrations before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 min to +105 minutes
Other Comparison of mean BG concentrations Comparison of mean blood glucose concentrations before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other Comparison of the depth of BG hypoglycaemic events Comparison of the depth of blood glucose hypoglycaemic events before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other Comparison of the occurrence of BG hypoglycaemic events Comparison of the occurrence of blood glucose hypoglycaemic events before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other ?BGexercise: Comparison of the changes in BG during exercise ?BGexercise: Comparison of the changes in blood glucose during exercise before, during physical exercise (i.e., 0 min to +45min) 0 minutes to +45 minutes
Other ?iGexercise: Comparison of the changes in iG during exercise ?iGexercise: Comparison of the changes in interstitial glucose during exercise during physical exercise (i.e., 0 min to +45min) 0 minutes to +45 minutes
Other ?iGfeeding: Comparison of the changes in iG after feeding ?iGfeeding: Comparison of the changes in interstitial glucose after feeding before physical exercise (i.e., -90 min to 0 min) -90 minutes to 0 minutes
Other Comparison of TBR level 2 in iG values Comparison of the amount of time spent with interstitial glucose values below the target range level 2 before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other Comparison of TBR level 1 in iG values Comparison of the amount of time spent with interstitial glucose values below the target range level 1 before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other Comparison of TAR level 1 in iG values Comparison of the amount of time spent with interstitial glucose values above the target range level 1 before, during and for 1 hour after physical exercise (i.e., -0 min to +105min) -90 minutes to +105 minutes
Other Comparison of TAR level 2 in iG values Comparison of the amount of time spent with interstitial glucose values after the target range level 2 before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other Comparison of mean iG concentrations Comparison of mean interstitial glucose concentrations before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other Comparison of the standard deviation in iG concentrations Comparison of the standard deviation in interstitial glucose concentrations before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other Comparison of the coefficient of variation in iG concentrations Comparison of the coefficient of variation in interstitial glucose concentrations before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other Comparison of the minimum iG concentration Comparison of the minimum interstitial glucose concentration before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Other Comparison of the maximum iG concentration Comparison of the maximum interstitial glucose concentration before, during and for 1 hour after physical exercise (i.e., -90 min to +105min) -90 minutes to +105 minutes
Primary Comparison of TIR in blood glucose values during, and 1-hour after, dynamic physical exercise Comparison of the amount of time spent with blood glucose values within the target range during, and 1-hour after, dynamic physical exercise 0 minutes to +105 minutes
Secondary To compare the influence of carbohydrate feeding before versus during exercise on the physiological responses to dynamic physical exercise To compare the influence of carbohydrate feeding before versus during exercise on the physiological responses to dynamic physical exercise 0 minutes to +45 minutes
See also
  Status Clinical Trial Phase
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Completed NCT03667053 - Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children Phase 3
Active, not recruiting NCT03422471 - Hypoglycemia and Autonomic Nervous System Function- B2 N/A
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05597605 - The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects N/A
Not yet recruiting NCT05990933 - Role of Adrenaline in in the Inflammatory Response in Diabetes N/A
Withdrawn NCT03736083 - Introducing CGM at Type 1 Diabetes Diagnosis N/A
Completed NCT02966275 - Post Bariatric Closed Loop Glucagon Trial N/A
Not yet recruiting NCT02909881 - Dose Response Oxidation of a Sweet-corn Derived Sugar (PhytoSpherix) During Exercise in Endurance Trained Athletes N/A
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Completed NCT02213003 - Allogeneic Islet Cells Transplanted Onto the Omentum Phase 1/Phase 2
Completed NCT01147276 - Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes Phase 4
Completed NCT01176656 - Hypoglycemia: Physician and Patient Perspectives N/A
Completed NCT00998374 - Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge N/A
Terminated NCT01225159 - Tight Glycaemic Control During Cardiac Surgery N/A
Completed NCT00373854 - Study of How Low Blood Sugar Affects the Way Blood Vessels Work N/A
Completed NCT00285233 - Delayed Mycophenolate Mofetil in Single-Donor Islet Allotransplantation in Type 1 Diabetes Phase 1/Phase 2
Recruiting NCT05916131 - Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management. N/A
Terminated NCT04026750 - Insulin Tolerance Test Study in Patients With Type 1 Diabetes Phase 1
Recruiting NCT04192422 - DiGESTnewborn Study